selvanegra/iStock via Getty Images
Investment Thesis
The FDA’s controversial approval of Biogen’s (BIIB) Alzheimer’s Disease therapy Aduhelm, despite its questionable efficacy profile, has had a transformative effect on the share prices of a number of…

Click here to view the original article.